Loading patent…
AssigneesB.G. Negev Technologies and Applications Ltd., Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
InventorsIrun R. Cohen, Bracha Rager-Zisman, Angel Porgador, Johannes Herkel
Estimating the term…
The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.
A vaccine composition comprising an antigen and a synthetic peptide adjuvant comprising a T cell epitope of HSP60 in which the synthetic peptide adjuvant has an amino acid sequence selected from the group consisting of KKARVEDALHATRAAVEEGV (Ec27;
A conjugate comprising a viral antigen covalently attached to a synthetic peptide carrier comprising a T cell epitope of HSP60 in which said synthetic peptide carrier has an amino acid sequence selected from the group consisting of KKARVEDALHATRAAVEEGV (Ec27;
A method of enhancing the immunogenicity of an antigen comprising covalently conjugating the antigen with a synthetic peptide carrier having an amino acid sequence as set forth in any one of SEQ ID NOS:76 and 86 and analogs and derivatives thereof.
An isolated peptide antigen having an amino acid sequence selected from the group consisting of:
Dependencies are inferred from the claim text.